The forecast for antiarrhythmic medicine sales in South Korea shows a consistent increase from 2024 through 2028, with values growing from 0.6 USD per capita in 2024 to 0.8 USD per capita by 2028. This indicates a positive trend after a steady state in the previous years. The year-on-year variation shows a 16.7% increase from 2024 to 2025, maintaining this trend through 2027 and stabilizing thereafter. Over the last two years (2026-2028), the values reveal no percentage growth, indicating a plateau. The CAGR over the last five years stands at approximately 7.3%, reflecting moderate and sustained market growth. Future trends to watch for include potential market saturation, the introduction of new, more effective therapies, changes in medical guidelines, and the influence of technological advancements in diagnostics and monitoring that might impact the demand for antiarrhythmics.
• Consistent growth in antiarrhythmic medicine sales from 2024 to 2028.
• Year-on-year variation shows the most significant increase between 2024 and 2027, then stabilizes.
• An average annual growth rate (CAGR) of 7.3% over five years.
• Future trends: market saturation, new therapies, changes in guidelines, advancements in diagnostics and monitoring.